List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
AstraZeneca and Acerta Pharma have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
19 February 2016 | By Victoria White
After the first year, patients with a history of heart attack can now continue to be treated with Brilique at the lower dose of 60mg twice daily...
19 February 2016 | By Victoria White
In combination with the current standard of care, Zurampic provides a dual mechanism of action to increase excretion and decrease production of uric acid...
8 February 2016 | By EBD Group
The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016...
3 February 2016 | By Victoria White
The European Commission (EC) has granted conditional marketing authorisation for AstraZeneca's Tagrisso (AZD9291, osimertinib) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
29 January 2016 | By Victoria White
Allergan and AstraZeneca are to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam...
28 January 2016 | By Victoria White
This Lynparza BTD is for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer...
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
11 January 2016 | By Victoria White
Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…
23 December 2015 | By Victoria White
The FDA has approved AstraZeneca’s Zurampic (lesinurad) in combination with xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout...
18 December 2015 | By Victoria White
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of AstraZeneca’s Tagrisso (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small…
18 December 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending the marketing authorisation of lesinurad 200mg tablets for the adjunctive treatment of hyperuricaemia in adult gout patients...
Following the news earlier this week that AstraZeneca had been in acquisition talks with Acerta Pharma, AstraZeneca today announced that it is to invest in a majority equity stake in the company.
17 December 2015 | By Victoria White
AstraZeneca is to acquire the core respiratory business of Takeda for $575 million, adding Daxas to its portfolio...
AstraZeneca today confirmed that it is in talks with Acerta Pharma to acquire the company in a potential deal worth $5 billion.
